Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: MOLECULAR TARGETED THERAPY - , . Treffer: 35
2019
Riedmann, K; Bassermann, F; Jost, PJ
[Kinase inhibitors in oncology : What is new?]
Internist (Berl). 2019; 60(5):540-544
Doi: 10.1007/s00108-019-0577-8
Web of Science
PubMed
FullText
FullText_MUG
2018
Li, M; Zhang, F; Su, Y; Zhou, J; Wang, W
Nanoparticles designed to regulate tumor microenvironment for cancer therapy.
Life Sci. 2018; 201(10):37-44
Doi: 10.1016/j.lfs.2018.03.044
Web of Science
PubMed
FullText
FullText_MUG
2017
Chao, MP; Gentles, AJ; Chatterjee, S; Lan, F; Reinisch, A; Corces, MR; Xavy, S; Shen, J; Haag, D; Chanda, S; Sinha, R; Morganti, RM; Nishimura, T; Ameen, M; Wu, H; Wernig, M; Wu, JC; Majeti, R
Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.
Cell Stem Cell. 2017; 20(3): 329-344.
Doi: 10.1016/j.stem.2016.11.018
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Cuppens, T; Annibali, D; Coosemans, A; Trovik, J; Ter Haar, N; Colas, E; Garcia-Jimenez, A; Van de Vijver, K; Kruitwagen, RP; Brinkhuis, M; Zikan, M; Dundr, P; Huvila, J; Carpén, O; Haybaeck, J; Moinfar, F; Salvesen, HB; Stukan, M; Mestdagh, C; Zweemer, RP; Massuger, LF; Mallmann, MR; Wardelmann, E; Mints, M; Verbist, G; Thomas, D; Gommé, E; Hermans, E; Moerman, P; Bosse, T; Amant, F
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Clin Cancer Res. 2017; 23(5):1274-1285
Doi: 10.1158/1078-0432.CCR-16-2149
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Goblirsch, M; Richtig, G; Slaby, O; Berindan-Neagoe, I; Gerger, A; Pichler, M
MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.
Pharmacogenomics. 2017; 18(10):1027-1038
Doi: 10.2217/pgs-2017-0004
Web of Science
PubMed
FullText
FullText_MUG
Schanza, LM; Seles, M; Stotz, M; Fosselteder, J; Hutterer, GC; Pichler, M; Stiegelbauer, V
MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Int J Mol Sci. 2017; 18(11):
Doi: 10.3390/ijms18112495
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
He, JC; Yao, W; Wang, JM; Schemmer, P; Yang, Y; Liu, Y; Qian, YW; Qi, WP; Zhang, J; Shen, Q; Yang, T
TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
Oncotarget. 2016; 7(46):75441-75456
Doi: 10.18632/oncotarget.12254
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Kadletz, L; Bigenzahn, J; Thurnher, D; Stanisz, I; Erovic, BM; Schneider, S; Schmid, R; Seemann, R; Birner, P; Heiduschka, G
Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
Head Neck. 2016; 38 Suppl 1(8):E1918-E1925
Doi: 10.1002/hed.24349
Web of Science
PubMed
FullText
FullText_MUG
Konya, V; Mjösberg, J
Lipid mediators as regulators of human ILC2 function in allergic diseases.
Immunol Lett. 2016; 179:36-42
Doi: 10.1016/j.imlet.2016.07.006
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Rainer, PP; Kass, DA
Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.
Cardiovasc Res. 2016; 111(2):154-162
Doi: 10.1093/cvr/cvw107
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Schauberger, E; Peinhaupt, M; Cazares, T; Lindsley, AW
Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets.
Curr Allergy Asthma Rep. 2016; 16(7):48-48
Doi: 10.1007/s11882-016-0628-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Uttarkar, S; Dassé, E; Coulibaly, A; Steinmann, S; Jakobs, A; Schomburg, C; Trentmann, A; Jose, J; Schlenke, P; Berdel, WE; Schmidt, TJ; Müller-Tidow, C; Frampton, J; Klempnauer, KH
Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
Blood. 2016; 127(9):1173-1182
Doi: 10.1182/blood-2015-09-668632
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
Bochis, OV; Irimie, A; Pichler, M; Berindan-Neagoe, I
The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
J Gastrointestin Liver Dis. 2015; 24(2):225-234
Doi: 10.15403/jgld.2014.1121.242.skp2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Mayr, C; Neureiter, D; Wagner, A; Pichler, M; Kiesslich, T
The role of polycomb repressive complexes in biliary tract cancer.
Expert Opin Ther Targets. 2015; 19(3):363-375
Doi: 10.1517/14728222.2014.986460
Web of Science
PubMed
FullText
FullText_MUG
Stotz, M; Gerger, A; Haybaeck, J; Kiesslich, T; Bullock, MD; Pichler, M
Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
Anticancer Res. 2015; 35(11):5737-5744
Web of Science
PubMed
Thomas, J; Ohtsuka, M; Pichler, M; Ling, H
MicroRNAs: Clinical Relevance in Colorectal Cancer.
Int J Mol Sci. 2015; 16(12):28063-28076
Doi: 10.3390/ijms161226080
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Wenzl, K; Troppan, K; Neumeister, P; Deutsch, AJ
The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms.
Curr Drug Targets. 2015; 16(1):38-46
Doi: 10.2174/1389450115666141120112818
Web of Science
PubMed
FullText
FullText_MUG
2014
Bisping, E; Wakula, P; Poteser, M; Heinzel, FR
Targeting cardiac hypertrophy: toward a causal heart failure therapy.
J Cardiovasc Pharmacol. 2014; 64(4):293-305
Doi: 10.1097/FJC.0000000000000126
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Olschewski, A; Papp, R; Nagaraj, C; Olschewski, H
Ion channels and transporters as therapeutic targets in the pulmonary circulation.
Pharmacol Ther. 2014; 144(3):349-368
Doi: 10.1016/j.pharmthera.2014.08.001
Web of Science
PubMed
FullText
FullText_MUG
Peintinger, F
Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?
Curr Opin Obstet Gynecol. 2014; 26(1):21-26
Doi: 10.1097/GCO.0000000000000041
Web of Science
PubMed
FullText
FullText_MUG
Pichler, M; Winter, E; Ress, AL; Bauernhofer, T; Gerger, A; Kiesslich, T; Lax, S; Samonigg, H; Hoefler, G
miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
J Clin Pathol. 2014; 67(3):198-203
Doi: 10.1136/jclinpath-2013-201904
Web of Science
PubMed
FullText
FullText_MUG
Smolle, E; Taucher, V; Haybaeck, J
Malignant ascites in ovarian cancer and the role of targeted therapeutics.
Anticancer Res. 2014; 34(4):1553-1561
Web of Science
PubMed
Smolle, E; Taucher, V; Petru, E; Haybaeck, J
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Anticancer Res. 2014; 34(4):1519-1530
Web of Science
PubMed
Stiegelbauer, V; Perakis, S; Deutsch, A; Ling, H; Gerger, A; Pichler, M
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
World J Gastroenterol. 2014; 20(33):11727-11735
Doi: 10.3748/wjg.v20.i33.11727
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Williams, SK; Maier, O; Fischer, R; Fairless, R; Hochmeister, S; Stojic, A; Pick, L; Haar, D; Musiol, S; Storch, MK; Pfizenmaier, K; Diem, R
Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
PLoS One. 2014; 9(2):e90117-e90117
Doi: 10.1371/journal.pone.0090117
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2013
Greene, SJ; Gheorghiade, M; Borlaug, BA; Pieske, B; Vaduganathan, M; Burnett, JC; Roessig, L; Stasch, JP; Solomon, SD; Paulus, WJ; Butler, J
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction.
J Am Heart Assoc. 2013; 2(6):e000536-e000536
Doi: 10.1161/JAHA.113.000536
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Li, K; Fichna, J; Schicho, R; Saur, D; Bashashati, M; Mackie, K; Li, Y; Zimmer, A; Göke, B; Sharkey, KA; Storr, M
A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.
Neuropharmacology. 2013; 71(3):255-263
Doi: 10.1016/j.neuropharm.2013.03.029
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Sbiera, S; Kroiss, M; Thamm, T; Beyer, M; Majidi, F; Kuehner, D; Wobser, M; Becker, JC; Adam, P; Ronchi, C; Allolio, B; Fassnacht, M;
Survivin in Adrenocortical Tumors Pathophysiological Implications and Therapeutic Potential.
HORMONE METAB RES. 2013; 45(2): 137-146.
Doi: 10.1055/s-0032-1327750
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Smolle, E; Taucher, V; Pichler, M; Petru, E; Lax, S; Haybaeck, J
Targeting signaling pathways in epithelial ovarian cancer.
Int J Mol Sci. 2013; 14(5):9536-9555
Doi: 10.3390/ijms14059536
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
van Oosterwijk, JG; Meijer, D; van Ruler, MA; van den Akker, BE; Oosting, J; Krenács, T; Picci, P; Flanagan, AM; Liegl-Atzwanger, B; Leithner, A; Athanasou, N; Daugaard, S; Hogendoorn, PC; Bovée, JV
Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
Am J Pathol. 2013; 182(4):1347-1356
Doi: 10.1016/j.ajpath.2012.12.036
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2012
Grunewald, TGP; Greulich, N; Kontny, U; Fruhwald, M; Rutkowski, S; Kordes, U; Scheurlen, W; Schmidt, W; Stachel, D; Metzler, M; Mittler, U; Graf, N; Benesch, M; Burdach, S
Targeted Therapeutics in Treatment of Children and Young Adults with Solid Tumors: an Expert Survey and Review of the Literature
Klin Padiatr. 2012; 224(3):124-131
Doi: 10.1055/s-0032-1301930
Web of Science
PubMed
FullText
FullText_MUG
Laimer, D; Dolznig, H; Kollmann, K; Vesely, PW; Schlederer, M; Merkel, O; Schiefer, AI; Hassler, MR; Heider, S; Amenitsch, L; Thallinger, C; Staber, PB; Simonitsch-Klupp, I; Artaker, M; Lagger, S; Turner, SD; Pileri, S; Piccaluga, PP; Valent, P; Messana, K; Landra, I; Weichhart, T; Knapp, S; Shehata, M; Todaro, M; Sexl, V; Höfler, G; Piva, R; Medico, E; Ruggeri, BA; Cheng, M; Eferl, R; Egger, G; Penninger, JM; Jaeger, U; Moriggl, R; Inghirami, G; Kenner, L
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Nat Med. 2012; 18(11):1699-1704
Doi: 10.1038/nm.2966
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Scheipl, S; Froehlich, EV; Leithner, A; Beham, A; Quehenberger, F; Mokry, M; Stammberger, H; Varga, PP; Lazary, A; Windhager, R; Gattenloehner, S; Liegl, B
Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
Histopathology. 2012; 60(6):999-1003
Doi: 10.1111/j.1365-2559.2012.04186.x
Web of Science
PubMed
FullText
FullText_MUG
2011
De Vuyst, E; Boengler, K; Antoons, G; Sipido, KR; Schulz, R; Leybaert, L
Pharmacological modulation of connexin-formed channels in cardiac pathophysiology.
Br J Pharmacol. 2011; 163(3):469-483
Doi: 10.1111/j.1476-5381.2011.01244.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2010
Wackernagel, W; Lackner, EM; Pilz, S; Mayer, C; Stepan, V
von Hippel-Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumab.
ACTA OPHTHALMOL. 2010; 88(7): e271-e272.
Doi: 10.1111/j.1755-3768.2009.01611.x
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG